HigherHighs
RankingLoading... stocks
USA
NASDAQ
Healthcare
Biotechnology
NAMS (USA) - NewAmsterdam Pharma Company N.V. Ordinary Shares
1W
1M
3M
6M
1Y
2Y
5Y
All
ABOUT NewAmsterdam Pharma Company N.V. Ordinary Shares
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.